An evaluation of 2-deoxy-2-[ 18F]fluoro-d-glucose and 3′-deoxy-3′-[ 18F]-fluorothymidine uptake in human tumor xenograft models

Molecular Imaging and Biology

Volumn 14, Issue 3, 2012, Pages 355-365

  Keen, Heather ^a   Pichler, Bernd ^b   Kukuk, Damaris ^b   Duchamp, Olivier ^c   Raguin, Olivier ^c   Shannon, Aoife ^d   Whalley, Nichola ^a   Jacobs, Vivien ^a   Bales, Juliana ^a   Gingles, Neill ^a   Ricketts, Sally Ann ^a   Wedge, Stephen R ^a  

^a ASTRAZENECA   (United Kingdom)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c Oncodesign   (France)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

2 Deoxy 2 18F fluoro D glucose; 3 Deoxy 3 18F fluorothymidine; Human tumor models; PET

Indexed keywords

3' FLUOROTHYMIDINE F 18; FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; HEXOKINASE; HEXOKINASE 1; HEXOKINASE 2; HISTONE H3; KI 67 ANTIGEN; PHOSPHOHISTONE H3; THYMIDINE KINASE 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SCREENING; CELL PROLIFERATION; DRUG UPTAKE; FEMALE; GLUCOSE TRANSPORT; HISTOPATHOLOGY; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE TRACING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RADIOISOTOPE DISTRIBUTION; TUMOR CELL LINE; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; DIDEOXYNUCLEOSIDES; FEMALE; FLUORODEOXYGLUCOSE F18; HISTOCYTOCHEMISTRY; HUMANS; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; POSITRON-EMISSION TOMOGRAPHY; RESEARCH DESIGN; TRANSPLANTATION, HETEROLOGOUS; TUMOR MARKERS, BIOLOGICAL; WHOLE BODY IMAGING;

MUS;

EID: 84861481460     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-011-0504-4     Document Type: Article

References (52)

1. Hawkins RA, Choi Y, Huang SC, Messa C, Hoh CK, Phelps ME (1992) Quantitating tumor glucose metabolism with FDG and PET. J Nucl Med 33(3):339-344
2. Som P, Atkins HL, Bandoypadhyay D et al (1980) A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection. J Nucl Med 21(7):670-675 (Pubitemid 10034639)
3. Boellaard R, O'Doherty MJ, Weber WA et al (2010) FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 37(1):181-200
4. Hoekstra OS, Ossenkoppele GJ, Golding R et al (1993) Early treatment response in malignant lymphoma, as determined by planar fluorine-18- fluorodeoxyglucose scintigraphy. J Nucl Med 34(10):1706-1710 (Pubitemid 23295382)
5. Eary JF, O'Sullivan F, Powitan Y, Chandhury KR, Bruckner JD, Conrad EU (2002) Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med Mol Imaging 29(9):1149-1154 (Pubitemid 34985359)
6. Weber WA (2010) Monitoring tumor response to therapy with 18F-FLT PET. J Nucl Med 51(6):841-844
7. Benz MR, Czernin J, Tap WD et al (2010) FDG-PET/CT imaging predicts histopathologic treatment responses after neoadjuvant therapy in adult primary bone sarcomas. Sarcoma 2010:143540, Epub 2010 Apr 18
8. Weber WA (2009) Assessing tumor response to therapy. J Nucl Med 50 (Suppl 1):1S-10S
9. Bading JR, Shields AF (2008) Imaging of cell proliferation: status and prospects. J Nucl Med 49(Suppl 2):64S-80S (Pubitemid 351948037)
10. Shah C, Miller TW, Wyatt SK et al (2009) Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer. Clin Cancer Res 15(14):4712-4721
11. Sohn HJ, Yang YJ, Ryu JS et al (2008) [18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung. Clin Cancer Res 14(22):7423-7429
12. Leyton J, Alao JP, Da Costa M et al (2006) In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography. Cancer Res 66 ((15) (18)):9178-9185
13. Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, Aboagye EO (2007) Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F] fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 34:1339-1347 (Pubitemid 47312585)
14. Waldherr C, Mellinghoff IK, Tran C et al (2005) Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3′-deoxy-3′-18F-fluorothymidine PET. J Nucl Med 46:114-120 (Pubitemid 43086005)
15. Pio BS, Park CK, Pietras R et al (2006) Usefulness of 3′-[F-18]fluoro-3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol 8:36-42 (Pubitemid 44201576)
16. Troost EG, Bussink J, Hoffmann AL, Boerman OC, Oyen WJ, Kaanders JH (2010) 18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors. J Nucl Med 51(6):866-874
17. Solit D, Santos E, Pratilas DA, et al (2007) 3-Deoxy-3-[18F] fluorothymidine positron emission tomography is a sensitive method for imaging the response of BRAF dependent tumors to MEK inhibition. Cancer Res 67(23):11463-11469 (Pubitemid 350248575)
18. Brepoels L, Stroobants S, Verhoef G, De Groot T, Mortelmans L, De Wolf-Peeters C (2009) (18)F-FDG and (18)F-FLT uptake early after cyclophosphamide and mTOR inhibition in an experimental lymphoma model. J Nucl Med 50(7):1102-1109
19. Shinto A, Nair N, Dutt A, Baghel NS (2008) Early response assessment in gastrointestinal stromal tumors with FDG PET scan 24 hours after a single dose of imatinib. Clin Nucl Med 33(7):486-487
20. Gu J, Yamamoto H, Fukunaga H, Danno K et al (2006) Correlation of GLUT-1 overexpression, tumor size, and depth of invasion with 18F-2-fluoro-2-deoxy-D- glucose uptake by positron emission tomography in colorectal cancer. Dig Dis Sci 51(12):2198-2205
21. Juweid ME, Cheson BD (2006) Positron-emission tomography and assessment of cancer therapy. N Engl J Med 354(5):496-507 (Pubitemid 43200300)
22. Wahl RL, Hutchins GD, Buchsbaum DJ et al (1991) 18F-2-deoxy-2-fluoro-D- glucose uptake into human tumor xenografts. Feasibility studies for cancer imaging with positron-emission tomography. Cancer 67(6):1544-1550
23. Ebenhan T, Honer M, Ametamey SM et al (2009) Comparison of [18F]-tracers in various experimental tumor models by PET imaging and identification of an early response biomarker for the novel microtubule stabilizer patupilone. Mol Imaging Biol 11(5):308-321
24. Hendzel MJ, Wei Y, Mancini MA et al (1997) Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma 106(6):348-360 (Pubitemid 27510848)
25. Ladstein G, Bachmann IM, Straume O, Akslen LA (2010) Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma. BMC Cancer 10:140
26. Scholzen T, Gerdes J (2000) The Ki-67 protein: from the known and the unknown. J Cell Physiol 182(3):311-322 (Pubitemid 30054364)
27. Chung JK, Lee YJ, Kim SK, Jeong JM, Lee DS, Lee MC (2004) Comparison of [18F]fluorodeoxyglucose uptake with glucose transporter-1 expression and proliferation rate in human glioma and nonsmall-cell lung cancer. Nucl Med Commun 25(1):11-17 (Pubitemid 38183946)
28. Hamacher K, Coenen HH, Stöcklin G (1986) Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 27:235-238 (Pubitemid 17024868)
29. Reischl G, Blocher A, Wei R et al (2006) Simplified, automated synthesis of 3'-[18F]fluoro-3'-deoxy-thymidine ([18F]FLT) and simple method for metabolite analysis in plasma. Radiochim Acta 94:447-451
30. Kim JS, Lee JS, Im KC, et al (2007) Performance measurement of the microPET focus 120 scanner. J Nucl Med 48(9):1527-1535
31. Bao Q, Newport D, Chen M, Stout DB, Chatziioannou AF (2009) Performance evaluation of the Inveon dedicated PET preclinical tomograph based on the NEMA NU-4 standards. J Nucl Med 50:401-408
32. Gambhir S (2004) Quantitative assay development for pet (chapter 2). In: Phelps ME (ed) PET: molecular imaging and its biological applications. Springer, Berlin
33. McKay JS, Bigley A, Bell A et al (2006) A pilot evaluation of the use of tissue microarrays for quantitation of target distribution in drug discovery pathology. Exp Toxicol Pathol 57(3):181-193 (Pubitemid 43061189)
34. Smith NR, James NH, Oakley I et al (2007) Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts. Mol Cancer Ther 6(8):2198-2208 (Pubitemid 47294748)
35. Hickinson DM, Klinowska T, Speake G et al (2010) AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer. Clin Cancer Res 16(4):1159-1169
36. Kim SL, Kim EM, Cheong SJ et al (2009) The effect of PPAR-gamma agonist on (18)F-FDG uptake in tumor and macrophages and tumor cells. Nucl Med Biol 36(4):427-433
37. Lutz AM, Ray P, Willmann JK, Drescher C, Gambhir SS (2007) 2-Deoxy-2-[F-18]fluoro-D-glucose accumulation in ovarian carcinoma cell lines. Mol Imaging Biol 9(5):260-266 (Pubitemid 47304775)
38. Wang H, Zhang J, Tian J et al (2009) Using dual-tracer PET to predict the biologic behavior of human colorectal cancer. J Nucl Med 50 (11):1857-1864
39. Waki A, Katoa H, Yanoa R et al (1998) The importance of glucose transport activity as the rate-limiting step of 2-deoxyglucose uptake in tumor cells in vitro. Nucl Med Biol 25(7):593-597 (Pubitemid 28442723)
40. Kallinowski F, Schlenger KH, Runkel S et al (1989) Blood flow, metabolism, cellular microenvironment, and growth rate of human tumor xenografts. Cancer Res 49(14):3759-3764 (Pubitemid 19197393)
41. Bergstrom M, Monazzam A, Razifar P, Ide S, Josephsson R, Langstrom B (2008) Modeling spheroid growth, PET tracer uptake, and treatment effects of the Hsp90 inhibitor NVP-AUY922. J Nucl Med 49(7):1204-1210 (Pubitemid 351948032)
42. Jin Q, Agrawal L, Vanhorn-Ali Z, Alkhatib G (2006) GLUT-1-independent infection of the glioblastoma/astroglioma U87 cells by the human T cell leukemia virus type 1. Virology 353(1):99-110 (Pubitemid 44291777)
43. Haberkorn U, Ziegler SI, Oberdorfer F et al (1994) FDG uptake, tumor proliferation and expression of glycolysis associated genes in animal tumor models. Nucl Med Biol 21(6):827-834 (Pubitemid 24263576)
44. Hamada K, Tomita Y, Qiu Y et al (2008) 18F-FDG-PET of musculoskeletal tumors: a correlation with the expression of glucose transporter 1 and hexokinase II. Ann Nucl Med 22(8):699-705
45. de Geus-Oei LF, van Krieken JH, Aliredjo RP et al (2007) Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer 55 (1):79-87 (Pubitemid 46038871)
46. Seo S, Hatano E, Higashi T et al (2009) P-glycoprotein expression affects 18F-fluorodeoxyglucose accumulation in hepatocellular carcinoma in vivo and in vitro. Int J Oncol 34(5):1303-1312
47. van Waarde A, Been LB, Ishiwata K, Dierckx RA, Elsinga PH (2006) Early response of sigma-receptor ligands and metabolic PET tracers to 3 forms of chemotherapy: an in vitro study in glioma cells. J Nucl Med 47 (9):1538-1545 (Pubitemid 47544943)
48. McKinley E, Guleryuz S, Zhao P et al (2010) Thymidine salvage to reflect tumor cell proliferation: Implications for 18F-FLT PET as a biomarker in oncology. J Nucl Med 51:446, MEETING ABSTRACTS
49. Buck AK, Bommer M, Stilgenbauer S et al (2006) Molecular imaging of proliferation in malignant lymphoma. Cancer Res 66(22):11055-11061 (Pubitemid 44877006)
50. Buck AK, Kratochwil C, Glatting G et al (2007) Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT. Eur J Nucl Med Mol Imaging 34(11):1775-1782 (Pubitemid 47599048)
51. Schwartz JL, Tamura Y, Jordan R, Grierson JR, Krohn KA (2003) Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. J Nucl Med 44(12):2027-2032 (Pubitemid 40022149)
52. Workman P, Twentyman P, Balkwill F et al (1998) United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition). Br J Cancer 77(1):1-10 (Pubitemid 28029765)